Sulfinpyrazone

Sulfinpyrazone
Systematic (IUPAC) name
1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione
Clinical data
Trade names Apo-sulfinpyrazone
AHFS/Drugs.com monograph
MedlinePlus a682339
Routes of
administration
oral intravenous
Pharmacokinetic data
Protein binding 98–99%
Metabolism hepatic
Excretion renal
Identifiers
CAS Number 57-96-5 YesY
ATC code M04AB02
PubChem CID 5342
IUPHAR/BPS 5826
DrugBank DB01138 YesY
ChemSpider 5149 YesY
UNII V6OFU47K3W YesY
KEGG D00449 YesY
ChEBI CHEBI:9342 YesY
ChEMBL CHEMBL832 YesY
Chemical data
Formula C23H20N2O3S
Molar mass 404.48 g/mol
  (verify)

Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane.

Like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney.

Contraindications

Sulfinpyrazone must not be used in persons with renal impairment or a high rate of excretion of uric acid (hyperuricosuria).[1]

References

  1. Underwood M (June 2006). "Diagnosis and management of gout". BMJ 332 (7553): 1315–9. doi:10.1136/bmj.332.7553.1315. PMC 1473078. PMID 16740561.


This article is issued from Wikipedia - version of the Sunday, June 28, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.